Infraorbital–Infratrochlear Versus Transnasal Sphenopalatine Ganglion Block for Septorhinoplasty: A Prospective, Randomized, Double-Blind, Clinical Trial
Journal of Clinical Medicine · 2026-08-15 · 15 (16) · 6321
DOI: 10.3390/jcm15166321 ↗At a glance
Journal article in Journal of Clinical Medicine, published online on 2026-08-15. Written by Andaç Dedeoğlu and 4 co-authors. Institution: Department of Anesthesiology and Reanimation, TR HSU Diyarbakır Gazi Yaşargil TRH, 21070 Diyarbakır, Turkey. 29 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Background/Objectives: Regional anesthesia techniques are increasingly being incorporated into multimodal analgesia for septorhinoplasty. This study compared the postoperative analgesic efficacy and recovery profiles of infraorbital–infratrochlear (ION–ITN) nerve block and transnasal sphenopalatine ganglion (SPG) block techniques.
Methods
In this prospective, randomized, double-blind trial, 93 patients undergoing septorhinoplasty received bilateral ION–ITN block (n = 45) or transnasal SPG block (n = 48). The primary outcome was postoperative pain assessed using the Numerical Rating Scale (NRS). Peak postoperative NRS scores at the predefined assessment intervals were evaluated with a linear mixed-effects model adjusted for relevant covariates. Continuous variables are presented as medians (first quartile–third quartile [Q1–Q3]), and categorical variables as numbers (percentages). Secondary outcomes included emergence agitation (Riker Sedation–Agitation Scale (RSAS)), rescue tramadol use, patient satisfaction, and adverse events.
Results
Pain scores decreased significantly over time in both groups (p < 0.001). No significant group effect was observed (p = 0.726), and adjusted between-group differences were not significant at any postoperative interval (all p > 0.05). Although the group-by-time interaction showed a trend toward statistical significance (p = 0.053), no meaningful differences in postoperative pain trajectories were observed between the two groups. Median RSAS scores were lower in the SPG group (3 [2,3,4] vs. 4 [3,4], p = 0.04), whereas emergence agitation incidence, tramadol use, patient satisfaction, and adverse events were similar.
Conclusions
Within the multimodal analgesic regimen, no statistically significant differences in postoperative pain outcomes were detected between ION–ITN and transnasal SPG block. Because this study was not designed as an equivalence or non-inferiority trial, these findings should be interpreted as an absence of detected differences rather than proof of equivalent analgesic efficacy. Although SPG block was associated with lower agitation scores, this finding suggests reduced agitation severity rather than superior overall analgesic efficacy.
Subjects
Author keywords
Authors and institutions
- Department of Anesthesiology and Reanimation, TR HSU Diyarbakır Gazi Yaşargil TRH, 21070 Diyarbakır, Turkey.
ORCID profiles: Fatma Acil, Mehmet Özkılıç, Cem Kıvılcım Kaçar
Cite
APA
Dedeoğlu, A., Acil, F., Özkılıç, M., Soner, H. T., & Kaçar, C. K. (2026). Infraorbital–Infratrochlear Versus Transnasal Sphenopalatine Ganglion Block for Septorhinoplasty: A Prospective, Randomized, Double-Blind, Clinical Trial. Journal of Clinical Medicine, 15(16), 6321. https://doi.org/10.3390/jcm15166321
Vancouver
Dedeoğlu A, Acil F, Özkılıç M, Soner HT, Kaçar CK. Infraorbital–Infratrochlear Versus Transnasal Sphenopalatine Ganglion Block for Septorhinoplasty: A Prospective, Randomized, Double-Blind, Clinical Trial. Journal of Clinical Medicine. 2026;15(16):6321. doi:10.3390/jcm15166321
BibTeX
@article{Dedeolu2026,
author = {Dedeoğlu, Andaç and Acil, Fatma and Özkılıç, Mehmet and Soner, Hülya Tosun and Kaçar, Cem Kıvılcım},
title = {Infraorbital–Infratrochlear Versus Transnasal Sphenopalatine Ganglion Block for Septorhinoplasty: A Prospective, Randomized, Double-Blind, Clinical Trial},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {16},
pages = {6321},
doi = {10.3390/jcm15166321}
}
EUVIMED